

# Denise Nardelli-haeffliger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8049010/publications.pdf>

Version: 2024-02-01

49  
papers

1,703  
citations

279798

23  
h-index

289244

40  
g-index

49  
all docs

49  
docs citations

49  
times ranked

2165  
citing authors

#	ARTICLE	IF	CITATIONS
1	Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1128-1137.	6.3	205
2	ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. <i>Journal of Clinical Investigation</i> , 2017, 127, 2916-2929.	8.2	176
3	Nasal Immunization of Mice with Human Papillomavirus Type 16 Virus-Like Particles Elicits Neutralizing Antibodies in Mucosal Secretions. <i>Journal of Virology</i> , 1998, 72, 8220-8229.	3.4	149
4	Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. <i>Vaccine</i> , 2005, 23, 3634-3641.	3.8	93
5	A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection. <i>Journal of Virology</i> , 2011, 85, 13253-13259.	3.4	90
6	Mucosal but Not Parenteral Immunization with Purified Human Papillomavirus Type 16 Virus-Like Particles Induces Neutralizing Titers of Antibodies throughout the Estrous Cycle of Mice. <i>Journal of Virology</i> , 1999, 73, 9609-9613.	3.4	69
7	<i>Salmonella enterica</i> Serovar Typhi Ty21a Expressing Human Papillomavirus Type 16 L1 as a Potential Live Vaccine against Cervical Cancer and Typhoid Fever. <i>Vaccine Journal</i> , 2007, 14, 1285-1295.	3.1	60
8	Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. <i>Frontiers in Immunology</i> , 2019, 10, 622.	4.8	55
9	Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. <i>European Urology</i> , 2018, 74, 540-544.	1.9	53
10	Immunobiology of Human Papillomavirus Infection and Vaccination - Implications for Second Generation Vaccines. <i>Vaccine</i> , 2008, 26, K62-K67.	3.8	52
11	Chapter 17: Second generation HPV vaccines to prevent cervical cancer. <i>Vaccine</i> , 2006, 24, S147-S153.	3.8	46
12	Intravaginal Immunization of Mice with Recombinant <i>Salmonella enterica</i> Serovar Typhimurium Expressing Human Papillomavirus Type 16 Antigens as a Potential Route of Vaccination against Cervical Cancer. <i>Infection and Immunity</i> , 2008, 76, 1940-1951.	2.2	46
13	Trachea, Lung, and Tracheobronchial Lymph Nodes Are the Major Sites Where Antigen-Presenting Cells Are Detected after Nasal Vaccination of Mice with Human Papillomavirus Type 16 Virus-Like Particles. <i>Journal of Virology</i> , 2002, 76, 12596-12602.	3.4	40
14	Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion. <i>Oncotarget</i> , 2016, 7, 14015-14028.	1.8	40
15	The Nature of the Attenuation of <i>Salmonella typhimurium</i> Strains Expressing Human Papillomavirus Type 16 Virus-Like Particles Determines the Systemic and Mucosal Antibody Responses in Nasally Immunized Mice. <i>Infection and Immunity</i> , 1999, 67, 3674-3679.	2.2	38
16	A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers. <i>International Journal of Cancer</i> , 2011, 128, 2105-2113.	5.1	33
17	Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. <i>International Journal of Cancer</i> , 2011, 129, 762-772.	5.1	29
18	Targeting Cx40 (Connexin40) Expression or Function Reduces Angiogenesis in the Developing Mouse Retina. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 2136-2146.	2.4	29

#	ARTICLE	IF	CITATIONS
19	Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice. <i>Cancer Immunology Research</i> , 2018, 6, 1301-1313.	3.4	27
20	Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. <i>Antiviral Research</i> , 2007, 76, 75-85.	4.1	26
21	Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model. <i>Cancer Immunology Research</i> , 2019, 7, 621-629.	3.4	26
22	Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 717-725.	7.0	24
23	Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors. , 2019, 7, 122.		24
24	Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. <i>Vaccine</i> , 2009, 27, 2326-2334.	3.8	23
25	Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. <i>European Urology</i> , 2017, 71, 854-857.	1.9	22
26	Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2017, 6, e1265720.	4.6	19
27	Induction of human papillomavirus oncogene-specific CD8 T cell effector responses in the genital mucosa of vaccinated mice. <i>International Journal of Cancer</i> , 2010, 126, 2469-2478.	5.1	17
28	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. <i>Oncolmmunology</i> , 2015, 4, e1029702.	4.6	17
29	Vaccination Route Matters for Mucosal Tumors. <i>Science Translational Medicine</i> , 2013, 5, 172fs4.	12.4	16
30	Monitoring of Vaccine-Specific Gamma Interferon Induction in Genital Mucosa of Mice by Real-Time Reverse Transcription-PCR. <i>Vaccine Journal</i> , 2008, 15, 757-764.	3.1	15
31	The importance of mucosal immunity in defense against epithelial cancers. <i>Current Opinion in Immunology</i> , 2005, 17, 175-179.	5.5	14
32	Intravaginal and Subcutaneous Immunization Induced Vaccine Specific CD8 T Cells and Tumor Regression in the Bladder. <i>Journal of Urology</i> , 2014, 191, 814-822.	0.4	14
33	Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1125.	4.1	14
34	Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients. <i>Oncolmmunology</i> , 2012, 1, 694-698.	4.6	12
35	Intravaginal live attenuated <i>Salmonella</i> increases local antitumor vaccine-specific CD8+T cells. <i>Oncolmmunology</i> , 2013, 2, e22944.	4.6	12
36	Local <i>Salmonella</i> immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. <i>Oncolmmunology</i> , 2015, 4, e1016697.	4.6	11

#	ARTICLE	IF	CITATIONS
37	Targeting connexin37 alters angiogenesis and arteriovenous differentiation in the developing mouse retina. <i>FASEB Journal</i> , 2020, 34, 8234-8249.	0.5	10
38	Therapeutic efficacy of the live-attenuated <i>Mycobacterium tuberculosis</i> vaccine, MTBVAC, in a preclinical model of bladder cancer. <i>Translational Research</i> , 2018, 197, 32-42.	5.0	9
39	Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens. , 2020, 8, e000704.		8
40	Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model. <i>Oncolmmunology</i> , 2021, 10, 1912473.	4.6	8
41	What is the influence of vaccinationâ€™s routes on the regression of tumors located at mucosal sites?. <i>Oncolmmunology</i> , 2012, 1, 242-243.	4.6	6
42	Immunotherapeutic strategies for bladder cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 977-981.	3.3	6
43	Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients. <i>European Urology Focus</i> , 2022, 8, 748-751.	3.1	6
44	Siglec-7 May Limit Natural Killer Cellâ€™mediated Antitumor responses in Bladder Cancer Patients. <i>European Urology Open Science</i> , 2021, 34, 79-82.	0.4	5
45	Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2930.	4.1	4
46	Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. , 2022, 10, e004325.		4
47	Differentially regulated promoters for antigen expression in <i>Salmonella</i> vaccine strains. <i>Vaccine</i> , 2020, 38, 4154-4161.	3.8	1
48	Intramuscular Immunization Induces Antigen-specific Antibodies in Urine. <i>European Urology Focus</i> , 2020, 6, 280-283.	3.1	0
49	Mucosal vaccines for HPV. <i>Papillomavirus Report</i> , 2005, 16, 327-332.	0.2	0